Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GS-9911 + Zimberelimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GS-9911 | GS 9911|GS9911 | GS-9911 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (NCI Drug Dictionary). | ||
| Zimberelimab | GLS-010|AB122|AB-122|GLS010 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06082960 | Phase I | GS-9911 + Zimberelimab GS-9911 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | Active, not recruiting | USA | CAN | AUS | 0 |